DrugPatentWatch Database Preview
Drugs in Development Information for RG1662
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug RG1662?
RG1662 is an investigational drug.
There have been 9 clinical trials for RG1662.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Down Syndrome, Syndrome, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].
There are nine US patents protecting this investigational drug and one hundred and twenty international patents.
Summary for RG1662
| US Patents | 9 |
| International Patents | 120 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-05-01) |
| Vendors | 25 |
Recent Clinical Trials for RG1662
| Title | Sponsor | Phase |
|---|---|---|
| A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age | Hoffmann-La Roche | Phase 2 |
| A Brain Imaging Study to Assess GABAA Receptor Alpha5 Subunit Occupancy Following a Single Dose of RO5186582 in Japanese Healthy Volunteers. | Hoffmann-La Roche | Phase 1 |
| A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects | Hoffmann-La Roche | Phase 1 |
Clinical Trial Summary for RG1662
Top disease conditions for RG1662
Top clinical trial sponsors for RG1662
US Patents for RG1662
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RG1662 | Start Trial | Isoxazolo-pyridine derivatives | Hoffmann-La Roche Inc (Nutley, NJ) | Start Trial |
| RG1662 | Start Trial | Process for the preparation of isoxazolyl-methoxy nicotinic acids | Hoffman-La Roche Inc. (Nutley, NJ) | Start Trial |
| RG1662 | Start Trial | Solid forms | Hoffmann-La Roche Inc. (Nutley, NJ) | Start Trial |
| RG1662 | Start Trial | Use of selective GABA A .alpha.5 negative allosteric modulators for the treatment of central nervous system conditions | Hoffmann-La Roche Inc. (Nutley, NJ) | Start Trial |
| RG1662 | Start Trial | Isoxazolo-pyridine derivatives | Roche Palo Alto LLC (So. San Francisco, CA) | Start Trial |
| RG1662 | Start Trial | Isoxazolo-pyridine derivatives | Roche Palo Alto LLC (So. San Francisco, CA) | Start Trial |
| RG1662 | Start Trial | Isoxazolo-pyridine derivatives | Roche Palo Alto LLC (So. San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RG1662
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RG1662 | Argentina | 069523 | 2027-12-04 | Start Trial |
| RG1662 | Australia | 2008333326 | 2027-12-04 | Start Trial |
| RG1662 | Brazil | PI0820112 | 2027-12-04 | Start Trial |
| RG1662 | Canada | 2707648 | 2027-12-04 | Start Trial |
| RG1662 | Chile | 2008003591 | 2027-12-04 | Start Trial |
| RG1662 | China | 101889010 | 2027-12-04 | Start Trial |
| RG1662 | Colombia | 6351788 | 2027-12-04 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
